You have 9 free searches left this month | for more free features.

CD30, r/r NHL, DLBCL, ALCL, ENKTCL, PMBCL, PTCL, adult

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Lymphoma (B-ALL) Trial (PIT565)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma (B-NHL)
    • B-cell Acute Lymphoblastic Lymphoma (B-ALL)
    • PIT565
    • (no location specified)
    Jun 13, 2022

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

    Active, not recruiting
    • B-Cell Lymphoma
    • Non-Hodgkin Lymphoma
    • Birmingham, Alabama
    • +23 more
    Dec 2, 2022

    Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL Trial in United States (KT-413)

    Recruiting
    • Non Hodgkin Lymphoma
    • +3 more
    • Washington, District of Columbia
    • +5 more
    Nov 29, 2022

    Non-Hodgkin Lymphoma Trial in Worldwide (Epcoritamab, Lenalidomide, Ibrutinib)

    Recruiting
    • Non-Hodgkin Lymphoma
    • Tucson, Arizona
    • +81 more
    Jan 25, 2023

    DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Apr 10, 2023

    Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

    Completed
    • Non-Hodgkin's Lymphoma, Relapsed
    • +8 more
    • PBCAR20A
    • +2 more
    • Duarte, California
    • +4 more
    Jan 4, 2023

    Non-hodgkin Lymphoma Trial (HY004)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • HY004
    • (no location specified)
    Aug 21, 2023

    Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

    Not yet recruiting
    • Non Hodgkin's Lymphoma
    • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
    • +2 more
    • Beijing, China
    • +2 more
    Aug 23, 2023

    Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

    Not yet recruiting
    • Advanced Malignancies
    • 1A46 Drug Substance
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Aug 4, 2023

    Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma Trial in Worldwide (AZD4573)

    Recruiting
    • Relapsed/Refractory Peripheral T-cell Lymphoma
    • Relapsed/Refractory Classical Hodgkins Lymphoma
    • Duarte, California
    • +33 more
    Jan 5, 2023

    Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

    Not yet recruiting
    • Relapsed or Refractory Peripheral T-cell Lymphoma
    • Kaohsiung, Taiwan
    • +4 more
    Apr 17, 2023

    Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma Trial in Japan (tafasitamab, lenalidomide, parsaclisib)

    Recruiting
    • Non Hodgkins Lymphoma
    • Diffuse Large B-cell Lymphoma
    • Aichi, Japan
    • +4 more
    Jan 24, 2022

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin
    • +2 more
    • New York, New York
      Weill Cornell Medicine/NewYork-Presberteryian Hospital
    Jan 18, 2023

    DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +2 more
    • New Haven, Connecticut
    • +2 more
    Aug 22, 2022

    B-cell Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin)

    Recruiting
    • B-cell Non-Hodgkin Lymphoma
    • Mosunetuzumab (IV)
    • +4 more
    • Birmingham, Alabama
    • +28 more
    Jan 6, 2023

    Hematologic Cancer Trial in Israel, United States (ABBV-101)

    Not yet recruiting
    • Hematologic Cancer
    • Lone Tree, Colorado
    • +7 more
    Feb 22, 2023

    DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • Mitoxantrone Hydrochloride Liposome Injection
    • Jinan, Shandong, China
      Affiliated Cancer Hospital of Shandong First Medical University
    May 16, 2023

    Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

    Recruiting
    • Lymphoma
    • Relapse/Recurrence
    • Wuhan, Hubei, China
    • +1 more
    Apr 8, 2022

    DLBCL, Follicular Lymphoma Trial in United States (Epcoritamab)

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Follicular Lymphoma
    • Fountain Valley, California
    • +38 more
    Jul 27, 2022

    B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

    Recruiting
    • B-cell Non Hodgkin Lymphoma
    • regimen with BTK inhibitor +Anti-CD19 CAR T cells
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Feb 23, 2023

    Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

    Not yet recruiting
    • Mature B-Cell Non-Hodgkin Lymphoma
    • (no location specified)
    Sep 6, 2022